CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug—Suvorexant as an Example PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice. 24(2):104-110, March 2018. Abstract Abstract Favorites PDF Get Content & Permissions Buy
CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes—Tasimelteon as an Example PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice. 23(6):425-430, November 2017. Abstract Abstract Favorites PDF Get Content & Permissions Buy
CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade—Implications for the Field PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice. 23(5):352-360, September 2017. Abstract Abstract Favorites PDF Get Content & Permissions Buy
CNS Drug Development: Lessons Learned Part 2. Symptoms, Not Syndromes as Targets Consistent with the NIMH Research Domain Approach PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice. 21(1):60-66, January 2015. Abstract Abstract Favorites PDF Get Content & Permissions Buy
CNS Drug Development: Lessons from the Development of Ondansetron, Aprepitant, Ramelteon, Varenicline, Lorcaserin, and Suvorexant. Part I PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice. 20(6):460-465, November 2014. Abstract Abstract Favorites PDF Get Content & Permissions Buy
